Cardesium offers computer aided diagnosis solutions for patient-specific cardiac healthcare by creating a cardiac digital twin. We work with current clinical protocols to bring clinicians image-derived cardiac anatomical models that can be 3D-printed for surgical planning. Us ing these 3D-models , we also provide tailored biophysiological simulations that enhance diagnosis allowing for personalized healthcare and the design of apparatus such as cardiac nets, or synthetic valves.
Cardiovascular diseases (CVD) are the single biggest global cause of death and an immense economic burden; CVD is expected to be the most costly disease in the western world for decades (UK estimates are £19 billion annually). Treatments are typically based on broader population studies which might not be applicable to individuals, pushing clinics to move towards precision medicine.
In the cardiac field, most companies rely on Computed Tomography (CT) scans. As CT is an ionizing imaging modality (subjecting the patient to radiation) it can only be used in patients with an established heart condition, and companies require specific imaging protocols necessitating extra regulatory approval, or special contracts with insurance companies. At Cardesium, we use MRI images (non-ionizing) from existing protocols; allowing us to provide cardiac analysis for screening purposes on healthy individuals. Cardiac imaging suffers from artifacts, such as patient motion or breath-hold issues, which companies do not correct, causing bias in their diagnosis.
The Cardesium pipeline corrects for such artifacts using state-of-the-art machine learning and artificial intelligence algorithms. There is a real need for our tools if accurate and useful personalized models are to be made.
Our business model is B2B. We provide multiple packages on a case-by-case basis.
Package-1: patient-specific 3D shape model given a set of MRI images.
Package-2: additionally includes a diagnosis report giving established clinical metrics based on the shape.
Package-3: adds a comprehensive set of biophysiological simulations, providing useful information about the physiological state of the patient.
Our products not only help improve patient welfare through precision diagnosis, but also reduce the economic burden allowing collaboration with insurance companies to increase market penetration. By using our products, clinicians can reduce the probability of adverse effects, or deterioration in individuals, thereby reducing direct and indirect cardiac related costs.
Competitors such as Heartflow, Arterys, or Pie Medical imaging have estimated yearly revenues around $10-50 million. However, they focus on flow simulations rather than structural analysis. There is a clear market gap and a clinical need in the cardiac med-tech industry, which we aim to penetrate.
We have currently developed all the tools necessary to provide Package-1, which we are offering to a Japanese company producing cardiac nets. We have contracts for 2019 and are establishing future contracts, which will give Cardesium an initial yearly revenue. Yearly income projections for 2019: $2000, 2020: $26,000, 2021: $100,000, 2022: $400,000, 2023: $1.7M, 2024: $5M. 2025: $10M.
We aim to have regulatory approval for the shape models in the next 3-5 years. Cardesium was founded by Dr. Benjamin Villard and Dr. Ernesto Zacur, who have known and worked together for 6 years, both in and out of academia.
What are you pitching for?
We are currently looking for investment to take our venture forward (pre-seed /seed investment), as well as mentoring and collaboration. As we are a med-tech company, we would like to collaborate or be mentored by persons having experience in regulatory and Med-Tech financial sectors.